TW200302094A - 3 - (imidazolyl) -2- alkoxypropanoic acids - Google Patents

3 - (imidazolyl) -2- alkoxypropanoic acids Download PDF

Info

Publication number
TW200302094A
TW200302094A TW092100889A TW92100889A TW200302094A TW 200302094 A TW200302094 A TW 200302094A TW 092100889 A TW092100889 A TW 092100889A TW 92100889 A TW92100889 A TW 92100889A TW 200302094 A TW200302094 A TW 200302094A
Authority
TW
Taiwan
Prior art keywords
compound
group
hydrogen
formula
optionally substituted
Prior art date
Application number
TW092100889A
Other languages
English (en)
Chinese (zh)
Inventor
Charlotte Moira Norfor Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of TW200302094A publication Critical patent/TW200302094A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW092100889A 2002-01-22 2003-01-16 3 - (imidazolyl) -2- alkoxypropanoic acids TW200302094A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
TW200302094A true TW200302094A (en) 2003-08-01

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092100889A TW200302094A (en) 2002-01-22 2003-01-16 3 - (imidazolyl) -2- alkoxypropanoic acids

Country Status (24)

Country Link
EP (1) EP1467731A1 (fr)
JP (1) JP2005520811A (fr)
KR (1) KR20040077775A (fr)
CN (1) CN1620291A (fr)
AP (1) AP2004003084A0 (fr)
AR (1) AR038197A1 (fr)
BR (1) BR0307016A (fr)
CA (1) CA2472238A1 (fr)
EA (1) EA200400716A1 (fr)
EC (1) ECSP045200A (fr)
HR (1) HRP20040659A2 (fr)
IL (1) IL162677A0 (fr)
IS (1) IS7310A (fr)
MA (1) MA27167A1 (fr)
MX (1) MXPA04006573A (fr)
NO (1) NO20043457L (fr)
OA (1) OA12756A (fr)
PA (1) PA8563501A1 (fr)
PE (1) PE20030929A1 (fr)
PL (1) PL371487A1 (fr)
TN (1) TNSN04121A1 (fr)
TW (1) TW200302094A (fr)
UY (1) UY27615A1 (fr)
WO (1) WO2003061652A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (fr) * 2003-11-25 2005-06-09 Pfizer Limited Compositions pharmaceutiques stabilisees
JP2008536923A (ja) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心筋の再灌流の増強およびｐｃｉの容易化のためのｔａｆｉ阻害剤の使用
WO2010050525A1 (fr) 2008-10-29 2010-05-06 大正製薬株式会社 Composé ayant une activité inhibitrice des tafia
AU2009322342A1 (en) * 2008-12-05 2011-06-30 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
RS56445B1 (sr) * 2010-03-18 2018-01-31 Daiichi Sankyo Co Ltd Cikloalkil-supstituisani imidazolni derivat
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
AU2014280329A1 (en) 2013-06-10 2016-01-07 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
EP3437641A4 (fr) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited Agent thérapeutique contre les maladies inflammatoires de l'intestin
US11512067B2 (en) 2017-09-14 2022-11-29 Daiichi Sankyo Company, Limited Compound having cyclic structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
OA12362A (en) * 2000-08-17 2004-04-07 Pfizer Substituted imidazoles as tafia inhibitors.

Also Published As

Publication number Publication date
CA2472238A1 (fr) 2003-07-31
BR0307016A (pt) 2004-11-03
IL162677A0 (en) 2005-11-20
TNSN04121A1 (en) 2006-06-01
CN1620291A (zh) 2005-05-25
ECSP045200A (es) 2004-08-27
UY27615A1 (es) 2003-08-29
AP2004003084A0 (en) 2004-09-30
WO2003061652A1 (fr) 2003-07-31
WO2003061652A8 (fr) 2004-09-10
MXPA04006573A (es) 2004-10-04
EP1467731A1 (fr) 2004-10-20
PE20030929A1 (es) 2003-11-05
MA27167A1 (fr) 2005-01-03
PL371487A1 (en) 2005-06-13
HRP20040659A2 (en) 2004-10-31
EA200400716A1 (ru) 2004-12-30
JP2005520811A (ja) 2005-07-14
IS7310A (is) 2004-06-14
OA12756A (en) 2006-07-03
AR038197A1 (es) 2005-01-05
KR20040077775A (ko) 2004-09-06
PA8563501A1 (es) 2004-08-31
NO20043457L (no) 2004-08-19

Similar Documents

Publication Publication Date Title
CA2419633C (fr) Imidazoles substitues utilises comme inhibiteurs tafia
JP2003500387A (ja) Ｘａ因子の阻害剤
CA2615209A1 (fr) Nouvelles utilisations de composes d'agonistes du recepteur de mc4
CA2731897C (fr) Composes diazepines et diazocanes en tant qu'agonistes de mc4
TWI468396B (zh) 環丙烷羧酸衍生物及其用途
TW200302094A (en) 3 - (imidazolyl) -2- alkoxypropanoic acids
CN113677673B (zh) Trpc6的抑制剂
US6919457B2 (en) 3-(imidazolyl)-2-aminopropanoic acids
JP7051009B2 (ja) アミノペプチダーゼａ阻害剤及びそれを含む医薬組成物
MX2011004903A (es) Pirrolidinas.
US6713496B2 (en) 3-(imidazolyl)-2-alkoxypropanoic acids
JP2023099116A (ja) Ｒｅｔキナーゼ阻害剤としてのピラゾール誘導体
US6949577B2 (en) Pharmaceuticals
US20020147229A1 (en) Pharmaceuticals
AU2003237012A1 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
KR20200118088A (ko) 치료 화합물 및 조성물
JP2006527731A (ja) Ｘａ因子阻害剤としてのピロリジン−２−オン
ZA200301230B (en) Substituted imidazoles as tafia inhibitors.